IBDEI0SZ ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14028,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14028,1,3,0)
 ;;=3^838.05
 ;;^UTILITY(U,$J,358.3,14028,1,5,0)
 ;;=5^Dislocation of foot, closed dislocation; metatarsophalangeal(joint)
 ;;^UTILITY(U,$J,358.3,14028,2)
 ;;=^274398
 ;;^UTILITY(U,$J,358.3,14029,0)
 ;;=838.06^^74^852^29
 ;;^UTILITY(U,$J,358.3,14029,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14029,1,3,0)
 ;;=3^838.06
 ;;^UTILITY(U,$J,358.3,14029,1,5,0)
 ;;=5^Dislocation of foot, closed dislocation; interphalangeal(joint) foot
 ;;^UTILITY(U,$J,358.3,14029,2)
 ;;=^274399
 ;;^UTILITY(U,$J,358.3,14030,0)
 ;;=838.09^^74^852^30
 ;;^UTILITY(U,$J,358.3,14030,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14030,1,3,0)
 ;;=3^838.09
 ;;^UTILITY(U,$J,358.3,14030,1,5,0)
 ;;=5^Dislocation of foot, closed dislocation; other, toe(s)
 ;;^UTILITY(U,$J,358.3,14030,2)
 ;;=^274400
 ;;^UTILITY(U,$J,358.3,14031,0)
 ;;=12.5^1^74^852^19^-DIABETES MELLITUS^1^1
 ;;^UTILITY(U,$J,358.3,14031,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14031,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,14031,1,5,0)
 ;;=5
 ;;^UTILITY(U,$J,358.3,14032,0)
 ;;=64.5^1^74^852^22^-Dislocation^1^1
 ;;^UTILITY(U,$J,358.3,14032,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14032,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,14032,1,5,0)
 ;;=5
 ;;^UTILITY(U,$J,358.3,14033,0)
 ;;=459.10^^74^852^31
 ;;^UTILITY(U,$J,358.3,14033,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14033,1,3,0)
 ;;=3^459.10
 ;;^UTILITY(U,$J,358.3,14033,1,5,0)
 ;;=5^Post Phlebotic Syndrome
 ;;^UTILITY(U,$J,358.3,14033,2)
 ;;=Post Phlebotic Syndrome^328597
 ;;^UTILITY(U,$J,358.3,14034,0)
 ;;=719.7^^74^852^21
 ;;^UTILITY(U,$J,358.3,14034,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14034,1,3,0)
 ;;=3^719.7
 ;;^UTILITY(U,$J,358.3,14034,1,5,0)
 ;;=5^Difficulty In Walking
 ;;^UTILITY(U,$J,358.3,14034,2)
 ;;=^329945
 ;;^UTILITY(U,$J,358.3,14035,0)
 ;;=453.40^^74^852^8
 ;;^UTILITY(U,$J,358.3,14035,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14035,1,3,0)
 ;;=3^453.40
 ;;^UTILITY(U,$J,358.3,14035,1,5,0)
 ;;=5^Deep vein thrombosis lower extremity
 ;;^UTILITY(U,$J,358.3,14035,2)
 ;;=^338554
 ;;^UTILITY(U,$J,358.3,14036,0)
 ;;=357.2^^74^852^20
 ;;^UTILITY(U,$J,358.3,14036,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14036,1,3,0)
 ;;=3^357.2
 ;;^UTILITY(U,$J,358.3,14036,1,5,0)
 ;;=5^Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,14036,2)
 ;;=^96321
 ;;^UTILITY(U,$J,358.3,14037,0)
 ;;=250.60^^74^852^4
 ;;^UTILITY(U,$J,358.3,14037,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14037,1,3,0)
 ;;=3^250.60
 ;;^UTILITY(U,$J,358.3,14037,1,5,0)
 ;;=5^DM II w/ Neuro Manif
 ;;^UTILITY(U,$J,358.3,14037,2)
 ;;=^331803
 ;;^UTILITY(U,$J,358.3,14038,0)
 ;;=250.70^^74^852^6
 ;;^UTILITY(U,$J,358.3,14038,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14038,1,3,0)
 ;;=3^250.70
 ;;^UTILITY(U,$J,358.3,14038,1,5,0)
 ;;=5^DM II w/ Periph Circ Disorder
 ;;^UTILITY(U,$J,358.3,14038,2)
 ;;=^331807
 ;;^UTILITY(U,$J,358.3,14039,0)
 ;;=250.80^^74^852^5
 ;;^UTILITY(U,$J,358.3,14039,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14039,1,3,0)
 ;;=3^250.80
 ;;^UTILITY(U,$J,358.3,14039,1,5,0)
 ;;=5^DM II w/ Oth Manif
 ;;^UTILITY(U,$J,358.3,14039,2)
 ;;=^331811
 ;;^UTILITY(U,$J,358.3,14040,0)
 ;;=692.9^^74^853^1
 ;;^UTILITY(U,$J,358.3,14040,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14040,1,3,0)
 ;;=3^692.9
 ;;^UTILITY(U,$J,358.3,14040,1,5,0)
 ;;=5^Eczema
 ;;^UTILITY(U,$J,358.3,14040,2)
 ;;=^27800
 ;;^UTILITY(U,$J,358.3,14041,0)
 ;;=691.8^^74^853^2
 ;;^UTILITY(U,$J,358.3,14041,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14041,1,3,0)
 ;;=3^691.8
 ;;^UTILITY(U,$J,358.3,14041,1,5,0)
 ;;=5^Eczema, allergic
 ;;
 ;;$END ROU IBDEI0SZ
